Serine-reactive irreversible inhibitors

Serine-reactive irreversible inhibitors represent a pharmacological class of compounds rather than a specific biological target. These agents are characterized by their ability to form a stable, permanent covalent bond with the nucleophilic hydroxyl group of a serine residue, typically located within the catalytic triad of enzymes in the serine hydrolase superfamily (PMID: 28425720). This superfamily includes a diverse array of targets such as proteases, lipases, and esterases involved in critical physiological processes like lipid metabolism and neurotransmission (PMID: 21830831). By establishing a covalent adduct, these inhibitors provide a prolonged pharmacodynamic effect that is independent of the drug's systemic half-life, as enzymatic function can only be restored through the synthesis of new protein. While this mechanism is successfully utilized in therapeutic drugs like Orlistat for obesity and Saxagliptin for diabetes, it also characterizes the action of potent toxins such as organophosphate nerve agents (Source: PubChem). The development of such inhibitors requires high selectivity to minimize the risk of off-target modifications and the formation of drug-protein haptens that may trigger immune responses (PMID: 24591630).

Other names

Covalent serine inhibitorsSerine-directed irreversible inhibitorsSerine-modifying covalent agentsIrreversible serine hydrolase inhibitors

Irreversible covalent modification of the catalytic serine residue (typically via phosphorylation, sulfonation, carbamylation, or acylation) within the active site of an enzyme, leading to permanent loss of catalytic activity (PMID: 27012889).